Showing results (31-40 of 149) with videos related to

Sort By:
Pageof 15
Pharmacogenetics and Genomics|July 8, 2014
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatmentJoseph C Maranville, Rita Nanda, Gini F Fleming, et al.
Breast Cancer Research and Treatment|October 13, 2007
Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancersMinjie Wei, Jinhua Xu, James Dignam, et al.
Annals of Surgical Oncology|September 9, 2024
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast CancerJincong Q Freeman, Sarah P Shubeck, Nan Chen, et al.
JAMA Network Open|February 17, 2025
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the USJincong Q Freeman, Dezheng Huo, Sarah P Shubeck, et al.
JAMA Network Open|June 12, 2025
Clinical Trial Discussion and Participation in a Breast Cancer Cohort by Race and EthnicityNan Chen, Jincong Q Freeman, Fangyuan Zhao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 13, 2005
Phenotypic evaluation of the basal-like subtype of invasive breast carcinomaChad A Livasy, Gamze Karaca, Rita Nanda, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trialsOleg Gluz, Binghe Xu, Rita Nanda, et al.
Magnetic Resonance Imaging|August 23, 2023
Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancerZhen Ren, Federico D Pineda, Frederick M Howard, et al.
JAMA Oncology|February 23, 2023
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer DatabaseDaniel S Peiffer, Fangyuan Zhao, Nan Chen, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|December 9, 2024
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancerEmily Ly, Frederick M Howard, Nan Chen, et al.
Pageof 15